Bayer BAYRY has announced an exclusive license agreement with Cedilla Therapeutics to jointly develop and commercialize the latter’s CyclinE1/CDK2 complex inhibitors for targeted oncogenic ...

Cedilla Therapeutics, an oncology biotech founded by a former Editas executive, has snagged an additional $25 million to bring two small-molecule oncology programs into human trials. The financing ...

“Cedilla is proud to partner with Bayer on this exciting program,” said Neil Exter, Chief Executive Officer of Cedilla Therapeutics and Partner at Third Rock Ventures. “Cedilla's bespoke molecules are ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a preclinical biotech company harnessing protein stability to create the next generation of targeted cancer therapies, today announced the ...

Cedilla Therapeutics launched Tuesday with a $56 million investment from Third Rock and a mission to develop small molecules that target the stability of cancer-driving proteins. Others have ...

Bayer BAYRY has announced an exclusive license agreement with Cedilla Therapeutics to jointly develop and commercialize the latter’s CyclinE1/CDK2 complex inhibitors for targeted oncogenic ...